Profound Medical (TSE:PRN) Trading 0.3% Higher – Should You Buy?

Profound Medical Corp. (TSE:PRNGet Free Report)’s share price was up 0.3% during trading on Tuesday . The company traded as high as C$9.53 and last traded at C$9.43. Approximately 8,013 shares were traded during trading, a decline of 50% from the average session volume of 16,107 shares. The stock had previously closed at C$9.40.

Profound Medical Stock Performance

The firm has a market cap of C$342.67 million, a PE ratio of -7.60 and a beta of 1.26. The firm has a 50-day moving average price of C$9.45 and a two-hundred day moving average price of C$9.50. The company has a quick ratio of 14.98, a current ratio of 6.56 and a debt-to-equity ratio of 12.56.

Profound Medical (TSE:PRNGet Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported C$0.26 EPS for the quarter. Profound Medical had a negative return on equity of 78.75% and a negative net margin of 206.94%.The firm had revenue of C$7.42 million during the quarter. Research analysts forecast that Profound Medical Corp. will post -1.9000001 EPS for the current fiscal year.

Profound Medical Company Profile

(Get Free Report)

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.

Featured Articles

Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.